ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0469

IFNγ Is Essential for Alveolar Macrophage Driven Lung Inflammation in Macrophage Activation Syndrome

Denny Gao1, Maggie Henderlight1, Christopher Woods1, Alexei Grom1, Sherry Thornton1, Michael Jordan1, Katheryn Wikenheiser-Brokamp1 and Grant Schulert2, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

Meeting: ACR Convergence 2020

Keywords: innate immunity, interstitial lung disease, Juvenile idiopathic arthritis, macrophage activation syndrome, Mouse Models, Other

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: Pediatric Rheumatology – Basic Science (0469–0473)

Session Type: Abstract Session

Session Time: 5:00PM-5:50PM

Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening cytokine storm syndrome frequently complicating systemic juvenile idiopathic arthritis (SJIA) and driven by IFNγ. MAS is also associated with an emerging and severe inflammatory lung disease (SJIA-LD). The causes and pathogenesis of SJIA-LD are unknown, but have been proposed to include introduction of anti-cytokine therapies, allergic reactions, or other environmental factors, along with recurrent MAS. Our recent work supports activation of IFNγ pathways in the lungs of children with SJIA-LD, supporting a pathologic link between pulmonary inflammation and MAS. The objective of this study was to mechanistically define the novel observation of pulmonary inflammation in the TLR9 mouse model of MAS.

Methods: Pulmonary inflammation was examined by histopathology, cytokine/chemokine levels and alveolar macrophage gene expression profiling. IFNγ signaling was inhibited through neutralizing antibodies as well as using mice with macrophages insensitive to IFNγ.

Results: In acute MAS, lungs exhibit mild but diffuse lymphocyte-predominant, primarily perivascular interstitial inflammation with elevated IFNγ, elevated levels of the IFN-induced chemokines CXCL9 and CXCL10, and alveolar macrophage expression of IFNγ-induced genes. We have further developed the TLR9 model system by for the first time characterizing the resolution phase of MAS. MAS resolution was associated with alveolar macrophage expansion and increased interstitial mononuclear cell infiltration. Alveolar macrophage microarrays confirmed IFNγ-induced proinflammatory polarization during acute MAS. However, this switches towards an anti-inflammatory phenotype during MAS resolution with activation of STAT6-induced genes and repression of STAT1-induced genes. As many patients with SJIA-LD have repeated episodes of MAS, we retreated mice with CpG to model recurrent MAS. Interestingly, recurrent MAS led to increased alveolar inflammation, and reset alveolar macrophage polarization towards a persistent proinflammatory state. Furthermore, using both direct IFNg blockade and macrophages insensitive to IFNγ (MIIG) mice, both systemic feature of MAS and pulmonary inflammation were markedly attenuated.

Conclusion: These findings demonstrate that experimental MAS induces IFNγ-driven pulmonary inflammation that replicates key features of children with SJIA-LD. These findings support a model whereby MAS induces IFNγ-driven pulmonary inflammation and dynamic changes in alveolar macrophage polarization, contributing to development of SJIA-LD.


Disclosure: D. Gao, None; M. Henderlight, None; C. Woods, None; A. Grom, Novartis, 2, 5, SOBI, 2, 5, AB2Bio, 2, 5; S. Thornton, None; M. Jordan, SOBI, 5; K. Wikenheiser-Brokamp, None; G. Schulert, Novartis, 5, Sobi, 5.

To cite this abstract in AMA style:

Gao D, Henderlight M, Woods C, Grom A, Thornton S, Jordan M, Wikenheiser-Brokamp K, Schulert G. IFNγ Is Essential for Alveolar Macrophage Driven Lung Inflammation in Macrophage Activation Syndrome [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/ifn%ce%b3-is-essential-for-alveolar-macrophage-driven-lung-inflammation-in-macrophage-activation-syndrome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ifn%ce%b3-is-essential-for-alveolar-macrophage-driven-lung-inflammation-in-macrophage-activation-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology